Methods of administering amantadine
DCFirst Claim
Patent Images
1. A method of reducing OFF time in a patient with Parkinson'"'"'s disease (PD), wherein the patient is being treated with a Parkinson'"'"'s medication, the method comprising:
- (1) orally administering to said patient once daily for at least one week a first composition comprising 85 mg to 170 mg amantadine, or a pharmaceutically acceptable salt thereof, and at least one excipient that modifies the release of at least a portion of the amantadine or pharmaceutically acceptable salt thereof to provide an extended release form; and
thereafter(2) orally administering to said patient once daily a second composition comprising 260 mg to 380 mg amantadine, or a pharmaceutically acceptable salt thereof, and at least one excipient that modifies the release of at least a portion of the amantadine or pharmaceutically acceptable salt thereof to provide an extended release form;
wherein OFF time in the patient is reduced after at least 7 weeks of administering the second composition once daily to the patient; and
wherein the plasma concentration of amantadine in the patient is increased less than 10% at 1 hour after administration of the first or second composition.
2 Assignments
Litigations
0 Petitions
Accused Products
Abstract
Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.
267 Citations
56 Claims
-
1. A method of reducing OFF time in a patient with Parkinson'"'"'s disease (PD), wherein the patient is being treated with a Parkinson'"'"'s medication, the method comprising:
-
(1) orally administering to said patient once daily for at least one week a first composition comprising 85 mg to 170 mg amantadine, or a pharmaceutically acceptable salt thereof, and at least one excipient that modifies the release of at least a portion of the amantadine or pharmaceutically acceptable salt thereof to provide an extended release form; and
thereafter(2) orally administering to said patient once daily a second composition comprising 260 mg to 380 mg amantadine, or a pharmaceutically acceptable salt thereof, and at least one excipient that modifies the release of at least a portion of the amantadine or pharmaceutically acceptable salt thereof to provide an extended release form; wherein OFF time in the patient is reduced after at least 7 weeks of administering the second composition once daily to the patient; and wherein the plasma concentration of amantadine in the patient is increased less than 10% at 1 hour after administration of the first or second composition. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 51, 52, 53, 55, 56)
-
-
48. A method of reducing OFF time in a patient with Parkinson'"'"'s disease (PD), wherein the patient is being treated with a Parkinson'"'"'s medication, the method comprising:
-
(1) orally administering to said patient once daily for at least one week a first composition comprising 260 mg amantadine hydrochloride and at least one excipient that modifies the release of at least a portion of the amantadine hydrochloride to provide an extended release form; and
thereafter(2) orally administering to said patient once daily a second composition comprising 290 mg to 325 mg amantadine hydrochloride and at least one excipient that modifies the release of at least a portion of the amantadine hydrochloride to provide an extended release form; wherein OFF time in the patient is reduced after at least 7 weeks of administering the second composition once daily to the patient; and wherein the plasma concentration of amantadine in the patient is increased less than 10% at 1 hour after administration of the first or second composition. - View Dependent Claims (49, 50, 54)
-
Specification